Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01004172 · ClinicalTrials.gov registry record · Phase 2
Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT01004172 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 38 participants.
The verdict
NCT01004172, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine how well the combination of bevacizumab and carboplatin works in treating breast cancer that has spread to the brain. Bevacizumab is an antibody (a protein that attacks a foreign substance in the body) that is made in the laboratory. Bevacizumab works differently from the way chemotherapy drugs work. Usually chemotherapy drugs attack fast growing cancer cells in the body. Bevacizumab works to slow or stop the growth of cells in cancer tumors by decreasing the blood supply to the tumors. When the blood supply is decreased, the tumors don't get the oxygen and nutrients they need to grow. Carboplatin is in a class of drugs known as platinum-containing compounds and has been approved for use in the treatment of ovarian cancer. Information from other research studies suggests that the combination of bevacizumab with carboplatin may be effective in treating breast cancer.
Interventions
- DRUG carboplatin
- DRUG bevacizumab
- DRUG herceptin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2009-11 |
| Est. Completion | 2017-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01004172
The ClinicalTrials.gov registry entry for NCT01004172 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which carboplatin is the first listed.
NCT01004172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01004172 about?
NCT01004172 is a clinical study titled "Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases". The purpose of this research study is to determine how well the combination of bevacizumab and carboplatin works in treating breast cancer that has spread to the brain. Bevacizumab is an antibody (a protein that attacks a foreign substance in the body) that is made in the laboratory. Bevacizumab wor...
What is the current status of trial NCT01004172?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2009-11. Estimated completion is 2017-02.
What interventions are being tested in trial NCT01004172?
The interventions under investigation include: carboplatin (DRUG), bevacizumab (DRUG), herceptin (DRUG).
Who is sponsoring clinical trial NCT01004172?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.